2nd Annual MXene Global Conference To learn more about how ArgoPond can help your early-stage company, reach us at ArgoPond or by email at jyounger@argopond.com MXenes are transition metal carbides that can be synthesized as two-dimensional sheets. The more widely known 2D material, graphene, is beginning to enjoy commercial usage in a number of fields, including composite materials and energy storage. MXenes, although much earlier in their life cycle, hold similar promise.

What post-pandemic economic conditions mean for seed-stage life science ventures — Pyriscence: From the Latin, To open with fire. A strategy in plants for storing seeds until seedlings are most likely to find an environment supportive of new growth. Pyriscence in many conifers is the process by which seeds germinate only after being nearly destroyed in a forest fire. …

Championed as an excellent source of non-diluting capital, the funding mechanism carries a risk of decelerating and distracting teams on the way to market. — Small Business Innovation and Research grants — and their kin Small Business Technology Transfer grants — are commonly encountered in the financials of very early life science and deep-tech companies. Early investors from time to time consider backing companies that have previously received these awards. At other times, a company’s future fundraising may rely on the receipt of an SBIR award.

Mapping the US FDA 510(k) and Pre-Market Approval Landscape — With Bioeconomy.XYZ this year I’ve been building a story about the United State’s medical device innovation pipeline. The conversation started with a look at where NIH SBIR grant funding — one of the earliest types of funding for a new company — flows geographically across the nation. America’s Biggest Biotech Angel The NIH’s Billion Dollar Annual Boost to US Biotech Ecosystemsmedium.com

And identifying the niches where these companies most often thrive — Chances are, a medical device was among the first objects you touched when you arrived on Earth. Medical devices are ubiquitous in US healthcare— everything from the delivery room’s sterile gloves and umbilical cord clamps to the breathtakingly sophisticated neurosurgical operating room’s stereotactic navigation systems. More than ever medical devices are a fusion of hardware, software, and even synthetic living material. …

During the COVID-19 pandemic, Argo Pond provided research strategic advising and clinical trial oversight to research teams across the US. We are excited to present a series of interviews with some of these researchers, who effectively conducted clinical trials during a remarkable moment in history. In this blog, we speak…

During the COVID-19 pandemic, ArgoPond provided services to several research teams by leading clinical trial Data and Safety Monitoring Boards (DSMBs) and assisting with other clinical research strategic oversight. We are excited to present a series of interviews with some of these researchers, who effectively conducted clinical trials during a…

During the COVID-19 pandemic, ArgoPond provided services to several research teams by leading clinical trial Data and Safety Monitoring Boards (DSMBs) and assisting with other clinical research strategic oversight. We are excited to present a series of interviews with some of these researchers, who effectively conducted clinical trials during a…

The NIH’s Billion Dollar Annual Boost to US Biotech Ecosystems — The US National Institutes of Health (NIH) are the largest public supporter of basic life science in the world. With an FY2020 budget of $42 billion, most of their expenditures are university grants supporting either new discoveries or early-state clinical studies of promising treatments and diagnostic tests. Since 1982, Congress has mandated that a fraction of the total annual NIH budget be put to work via grants or contracts to small life science and biotech companies rather than academic institutions.